Reason for request
The actual benefit achieved with this proprietary medicinal product in this indication is moderate.
Improvement in actual benefit
Given the modest benefit observed and the risk of by no means negligible adverse reactions, Exelon provides a minor improvement in actual benefit (IAB IV) to patients with mild to moderately severe dementia associated with idiopathic Parkinson’s disease. The Commission notes that patients with visual hallucinations may particularly benefit from rivastigmine.